University Hospital Zürich
Welcome,         Profile    Billing    Logout  
 21 Trials 
42 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Müntener, Michael
NCT06776172: Extended Pelvic Lymph Node Dissection vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy in High-Grade Prostate Cancer Patients DISSECTION (2.0).

Not yet recruiting
N/A
400
Europe
Extended Pelvic Lymph Node Dissection, Extended Lymph Node Dissection
University Hospital, Basel, Switzerland
Prostate Cancer Surgery, Prostate Cancers
02/27
02/40
Ulrich, Silvia
NCT03537924: Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude

Active, not recruiting
4
100
RoW
ACETAZOLAMIDE oral capsule, Placebo oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Altitude Hypoxia
12/22
12/22
NCT03539367: Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude

Active, not recruiting
4
100
RoW
ACETAZOLAMIDE oral capsule, Placebo oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Altitude Hypoxia
12/22
12/22
NCT06498505: HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men

Recruiting
4
270
RoW
Acetazolamide, Placebo
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov, University Hospital Heidelberg, Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
High Altitude
12/25
12/25
NCT03540914: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.

Active, not recruiting
4
400
RoW
ACETAZOLAMIDE oral capsule, Placebo oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Altitude Hypoxia
12/24
12/24
NCT04915365: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude

Recruiting
3
100
RoW
Acetazolamide, Acetazolamide, oral capsule, Placebo, Placebo, oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine, Kyrgyz Republic
Right Heart Function, Chronic Obstructive Pulmonary Disease, Altitude Sickness
12/22
12/23
ESRA, NCT05339087: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH

Recruiting
2
70
Europe
Riociguat Oral Tablet, MK-4836, ATC Code: C02KX05, Placebo
Heidelberg University, Merck Sharp & Dohme LLC
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
10/25
06/26
PEGASUS, NCT03051763: The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension

Recruiting
N/A
1000
Europe
University of Giessen, Universitätsklinikum Hamburg-Eppendorf, DRK Kliniken Berlin Köpenick, Berlin, Germany, University Hospital, Zürich, University Hospital Carl Gustav Carus
Pulmonary Hypertension, Pulmonary Arterial Hypertension
12/21
05/22
NCT05185895: Visa-versa! Breaking Instead of Pushing the Pedals-D

Completed
N/A
24
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Healthy (Controls)
12/22
04/23
NCT05186987: Visa-versa! Breaking Instead of Pushing the Pedals-A

Completed
N/A
33
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Pulmonary Hypertension
08/23
09/23
HEXA, NCT04697875: Hemodynamic Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%)
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXASH, NCT04697862: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%) under Sildenafil, Normobaric hypoxia (FiO2 15%)
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXAS, NCT04704440: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension With/Without Sildenafil

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%), Normobaric hypoxia (FiO2 15%) under Sildenafil, Placebo-ambient air (FiO2 21%) under Sildenafil
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXASN, NCT04706546: Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil

Completed
N/A
24
Europe
Hemodynamic effect of exercise under Sildenafil, Hemodynamic effect of exercise
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXABM, NCT04715113: Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%), Normobaric hypoxia (FiO2 15%) under Sildenafil, Placebo-ambient air (FiO2 21%) under Sildenafil
University of Zurich
Hypertension, Pulmonary
05/23
05/23
PEX-NET, NCT03954574: Pulmonary Hemodynamics During Exercise - Research Network

Recruiting
N/A
1500
Europe, US, RoW
assessment of pulmonary hemodynamics during exercise by right heart catheterization
Medical University of Graz, European Respiratory Society
Pulmonary Circulation Diseases
12/29
12/29
NCT05185856: Visa-versa! Breaking Instead of Pushing the Pedals-B

Recruiting
N/A
16
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Chronic Obstructive Pulmonary Disease
07/24
12/24
NCT05204693: Visa-versa! Breaking Instead of Pushing the Pedals-C

Recruiting
N/A
16
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Left Heart Failure
12/23
07/24
NCT05996302: HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)

Active, not recruiting
N/A
24
Europe
Relocation to sea level
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06084559: HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)

Active, not recruiting
N/A
24
Europe
Supplemental oxygen therapy, Sham Oxygen therapy, Placebo
University of Zurich
Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06072417: HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)

Active, not recruiting
N/A
24
Europe
Assessment without intervention at High altitude, Relocation to sea level for 2 days
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06003244: High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)

Active, not recruiting
N/A
24
Europe
6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06385301: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases

Not yet recruiting
N/A
14
Europe
6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)
University of Zurich
Lung Disease Chronic, Lung Diseases, Interstitial, Lung Diseases, Obstructive
05/25
11/25
NCT06384534: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)

Not yet recruiting
N/A
28
Europe
6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen
University of Zurich
Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
05/25
11/25
NCT06489691: High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)

Not yet recruiting
N/A
24
RoW
6-minute walk test (6MWT)
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489717: High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)

Not yet recruiting
N/A
24
RoW
SDB assessment
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489704: High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

Not yet recruiting
N/A
24
RoW
Echocardiography
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489756: Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

Not yet recruiting
N/A
24
RoW
Echocardiography
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489743: Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

Not yet recruiting
N/A
24
RoW
6-minute walk test (6MWT)
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489730: HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

Not yet recruiting
N/A
120
NA
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
High Altitude Pulmonary Hypertension, Sleep Apnea
12/24
12/24
ZHPHCohort, NCT02249806: Zürich Pulmonary Hypertension Outcome Assessment Cohort

Recruiting
N/A
100
Europe
PH target therapy according to physician
University of Zurich
Pulmonary Hypertension Outcome Assessment
09/24
09/24
NCT05610631: Pulmonary Hypertension Registry Switzerland

Recruiting
N/A
1000
Europe
University of Zurich, Actelion
Pulmonary Hypertension
12/27
12/27
Segerer, Stephan
EMPASTONE, NCT06653738: Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention

Not yet recruiting
3
380
Europe
Empagliflozin 25 MG, Placebo, Personalized dietary counseling, Generic dietary counseling
Insel Gruppe AG, University Hospital Bern
Kidney Stone, Nephrolithiasis, Dietary Exposure
02/30
06/30
Curioni-Fontecedro, Alessandra
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
salVage, NCT06114108: Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Recruiting
N/A
128
Europe
Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Systemic therapy, Surgery, Radiotherapy
Swiss Group for Clinical Cancer Research
Non-small Cell Lung Cancer (NSCLC), Stage IV
11/27
11/27
Ritter, Alexander
EMPASTONE, NCT06653738: Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention

Not yet recruiting
3
380
Europe
Empagliflozin 25 MG, Placebo, Personalized dietary counseling, Generic dietary counseling
Insel Gruppe AG, University Hospital Bern
Kidney Stone, Nephrolithiasis, Dietary Exposure
02/30
06/30
Hoyos, Rodrigo Pesanez
NCT05996302: HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)

Active, not recruiting
N/A
24
Europe
Relocation to sea level
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06084559: HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)

Active, not recruiting
N/A
24
Europe
Supplemental oxygen therapy, Sham Oxygen therapy, Placebo
University of Zurich
Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06072417: HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)

Active, not recruiting
N/A
24
Europe
Assessment without intervention at High altitude, Relocation to sea level for 2 days
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06003244: High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)

Active, not recruiting
N/A
24
Europe
6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT04113044: Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®

Recruiting
N/A
3500
Europe, US, RoW
All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics., Patient Reported Outcomes
AO Innovation Translation Center
Hip Fractures, Tibial Fractures, Ankle Fractures, Humeral Fracture, Proximal, Distal Radius Fracture
12/26
12/26
Huber, Simone
NCT05524727: PEMOCS: Personalized Motor-cognitive Training in Chronic Stroke

Active, not recruiting
N/A
38
Europe
Concept-guided, personalized, motor-cognitive training by means of an exergame
University of Zurich
Stroke
07/24
07/24

Download Options